Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Florentino Lupercio Lopez

Clinical Cardiac Electrophysiology Daytona Beach, FL Medical Doctor

NPI 1871901793 CMS profile 7227895

305 Memorial Medical Pkwy Ste 300, Daytona Beach, FL 32117

Open in the dashboard

General payments

$18,613

438 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Florentino Lupercio Lopez of Daytona Beach, FL is reported in the CMS Open Payments database as having received $18,613 across 438 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 50th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,982 96
2024 General $2,621 106
2023 General $4,862 106
2022 General $1,858 53
2021 General $2,004 46
2020 General $2,726 24
2019 General $560 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Florentino Lupercio Lopez
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Florentino Lupercio Lopez were reported at $3,982. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Florentino Lupercio Lopez Clinical Cardiac Electrophysiology median Middle half National median
2019 $560 $2,361 $585–$8,260 $163
2020 $2,726 $993 $247–$4,351 $114
2021 $2,004 $1,185 $326–$4,739 $132
2022 $1,858 $2,073 $554–$6,789 $149
2023 $4,862 $2,568 $759–$8,159 $160
2024 $2,621 $2,557 $703–$7,403 $164
2025 $3,982 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biosense Webster, Inc. $4,318 151 payments
  2. Abbott Laboratories $2,693 37 payments
  3. Boston Scientific Corporation $2,205 22 payments
  4. Biotronik Inc. $1,999 11 payments
  5. Medtronic, Inc. $1,710 25 payments
  6. Medical Device Business Services, Inc. $829 5 payments
  7. Medtronic Vascular, Inc. $732 11 payments
  8. Novartis Pharmaceuticals Corporation $487 29 payments
  9. CVRx, Inc. $417 12 payments
  10. Merck Sharp & Dohme Corporation $404 21 payments
  11. Other $2,818 114 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,115 413 payments
  2. Travel and Lodging $3,802 19 payments
  3. Grant $1,400 1 payment
  4. Education $282 4 payments
  5. Consulting Fee $15 1 payment
Products named General payments · program years 2019–2025
  1. Carto 3 $4,951 149 payments
  2. GENERAL - BRADY $1,402 2 payments
  3. AVEIR $981 9 payments
  4. Acticor 7 VR-T DX $666 1 payment
  5. Selectra $666 1 payment
  6. VERQUVO $430 22 payments
  7. Barostim Neo System $417 12 payments
  8. Micra $367 6 payments
  9. Ensite Cardiac Mapping System $339 2 payments
  10. XARELTO $325 11 payments
  11. Other $7,970 249 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

859

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$407,702

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

43.4%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 154 $190,070
Xarelto Rivaroxaban Brand 78 $87,598
Entresto Sacubitril/Valsartan Brand 39 $56,296
Multaq Dronedarone Hcl Brand 26 $40,201
Jardiance Empagliflozin Brand 16 $24,147
Flecainide Acetate Generic 44 $1,455
Metoprolol Succinate Generic 79 $1,006
Rosuvastatin Calcium Generic 45 $871
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 14 $654
Olmesartan Medoxomil Generic 18 $627

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$483,513

Of which drugs: $345

Medicare patients

1,229

Average age 76

Services billed

4,647

574 women, 655 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 59%
Arthritis 58%
Ischemic heart disease 56%
Chronic kidney disease 49%
Heart failure 46%
Diabetes 40%
COPD 35%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 16 64 $345

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $74
$74 16 —
XARELTO
  • Janssen Pharmaceuticals, Inc $67
$67 78 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $63
$63 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $32
$32 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $30
$30 154 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

438 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record